Summary
The company's FY3/27 plan calls for revenue of JPY 7.6B and operating income of JPY 300M, with earnings weighted toward 2H. The key question for 2Q is how far the 1Q operating loss of JPY 179M narrows on a 1H cumulative basis. These are the first results to test the path to full-year profitability. On the top line, the first focus is whether Risk Management has bottomed after falling 18.6% YoY on the loss of a major client. The second is whether AI drug discovery can sustain its growth after rising 58.6% on accumulating co-creation projects. On costs, we will watch gross margin as the DX business takes a larger share of revenue and research headcount expands, along with Arunettsu's profitability. The 2Q cash flow statement will show how the increasingly debt-reliant balance sheet is holding up.
Key Points for Next Quarter
| Key Points & Focus | Implications |
|---|---|
P&L Progress1H cumulative operating income/loss and gross margin trend | Hitting the full-year recurring profit target of JPY 250M requires JPY +388M over the remaining three quarters (our estimate). Whether gross margin recovers from 38.7% in 1Q (52.4% a year earlier) will determine whether the 2H-weighted plan is achievable. |
Risk Management BusinessWhether the client-loss impact has run its course; revenue trend in Business Intelligence & Compliance Support | 1Q segment revenue was JPY 826M (-18.6%), with a segment loss of JPY 44M. A return to profitability depends on 2Q standalone revenue exceeding the 1Q level, helped by contributions from major financial institution projects. |
AI Drug DiscoveryAI drug discovery revenue and the size of the Life Science AI segment loss | 1Q AI drug discovery revenue was JPY 102M (+58.6%). We will check whether the segment loss of JPY 135M starts to narrow as the business absorbs research spending following the launch of the KIBIT AI Biology Lab. |
DX BusinessArunettsu's revenue growth and segment margin | 1Q DX segment revenue was JPY 694M (+64.4%), with segment income of JPY 24M (-31.8%). The prior-year 2Q was fully consolidated, so this quarter will reveal underlying revenue growth and profitability after hiring investments. |
Balance Sheet & Cash Flow2Q-end cash and deposits, borrowings, 1H cumulative operating CF | 1Q-end cash and deposits stood at JPY 1.446B, down JPY 287M from the prior fiscal year-end. Short-term borrowings were JPY 2.6B. We will gauge cash generation against prior-year 1H operating CF of JPY -102M. |
Key Issues from Previous Results (FY3/27 1Q Results)
1Q revenue was JPY 1.632B (+5.6%), with an operating loss of JPY 179M (vs. a JPY 82M loss a year earlier). Revenue growth in DX and AI drug discovery more than offset the decline in Risk Management. However, higher cost of goods sold cut gross profit from JPY 811M to JPY 631M and widened the loss. Management said its original plan was 2H-weighted and 1Q was in line with expectations, and it kept full-year guidance unchanged. 2Q will be the first chance to test that view against the numbers.
1. 1H Cumulative P&L Progress and Gross Margin Against the 2H-Weighted Plan
- Previous Quarter: 1Q posted an operating loss of JPY 179M and a recurring loss of JPY 138M, which management described as in line with expectations.
- Previous Quarter: Cost of goods sold rose to JPY 1B (+36.1%, our estimate), cutting gross margin to 38.7% from 52.4% a year earlier.
- Previous Quarter: SG&A was held down at JPY 810M (-9.2%, our estimate).
- To Verify This Quarter: The earnings release did not explain the higher cost ratio. We want to know whether the main driver is DX's larger revenue share or the expanded research headcount.
- To Verify This Quarter: Prior-year figures will be restated to reflect finalization of the provisional accounting for the business combination, so comparisons should use the restated figures.
- Key Metrics: 1H cumulative operating income/loss vs. JPY -5M in the prior-year period. Note that the prior-year figure was reported before the provisional accounting was finalized.
- Key Metrics: 1H cumulative gross margin vs. 38.7% in 1Q and 47.6% in prior-year 1H. We will also check whether full-year guidance is revised.
- Key Metrics: In 1Q, income taxes of JPY -23M made the net loss smaller than the recurring loss. We will check the breakdown of extraordinary items and income taxes for 1H.
2. Client-Loss Impact in Risk Management and Contribution from New Projects
- Previous Quarter: Segment revenue was JPY 826M (-18.6%), with a segment loss of JPY 44M (vs. JPY -0M a year earlier).
- Previous Quarter: Business Intelligence & Compliance Support revenue was JPY 234M (-34.4%). Major financial institution projects began to contribute, but the loss of large clients, including manufacturers, weighed on results.
- Previous Quarter: Economic Security revenue was JPY 64M (-33.0%). Management said government projects are planned with a 2H weighting.
- Previous Quarter: Legal Tech AI revenue was JPY 491M (-3.9%). Growth in digital forensics projects largely offset lower e-discovery activity.
- To Verify This Quarter: The key question is whether the client-loss impact runs its course in 2Q and revenue builds on contributions from financial institution projects.
- To Verify This Quarter: We will check whether cost restructuring, including the exit from overseas operations, shows up in segment earnings.
- Key Metrics: Risk Management 2Q standalone revenue vs. JPY 826M in 1Q, and the scale of improvement in segment earnings.
- Key Metrics: Business Intelligence & Compliance Support 2Q standalone revenue vs. JPY 234M in 1Q.
3. AI Drug Discovery: Balancing Deal Accumulation and Research Investment
- Previous Quarter: AI drug discovery revenue was JPY 102M (+58.6%), driven by more co-creation projects and DDAIF Innovation Bridge deals.
- Previous Quarter: AI medical device revenue was JPY 36M (-15.4%). Life Science AI segment revenue was JPY 139M (+29.2%).
- Previous Quarter: Growth investments, including expanded research headcount, widened the segment loss to JPY 135M (vs. JPY 118M a year earlier).
- Previous Quarter: The KIBIT AI Biology Lab, staffed by several dozen people, opened in May 2026. A new project with Astellas Pharma and a contract with Scohia Pharma are also underway.
- To Verify This Quarter: The key question is whether revenue from new projects can absorb the cost of the expanded research organization.
- To Verify This Quarter: The co-creation projects with Otsuka Pharmaceutical and Maruho (second phase), announced in October, will contribute from 3Q onward and will not affect 2Q earnings.
- To Verify This Quarter: The NB Health Laboratory project targets out-licensing as early as FY2026. We want management's view on when milestone revenue will be booked.
- Key Metrics: AI drug discovery 1H cumulative revenue vs. the prior-year period, and 2Q standalone revenue vs. JPY 102M in 1Q.
- Key Metrics: Life Science AI 2Q standalone segment earnings vs. JPY -135M in 1Q.
4. DX Business (Arunettsu): Underlying Growth and Profitability
- Previous Quarter: DX segment revenue was JPY 694M (+64.4%), of which external customer revenue was JPY 666M (+57.7%, our estimate).
- Previous Quarter: Upfront investments such as hiring held segment income to JPY 24M (-31.8%).
- Previous Quarter: Segment margin was 3.6%, down from 8.6% a year earlier (our estimate).
- Previous Quarter: From this fiscal year, Business Intelligence & Professional Support moved to Risk Management, leaving Arunettsu as the sole component of the DX business.
- To Verify This Quarter: Arunettsu was acquired on April 30, 2025, so 1Q's strong revenue growth may partly reflect a difference in consolidation periods versus the prior year.
- To Verify This Quarter: With the prior-year 2Q fully consolidated, 2Q will serve as the benchmark for underlying growth.
- To Verify This Quarter: We will also track how inter-segment eliminations (1Q adjustment of JPY -24M) affect consolidated operating income/loss.
- Key Metrics: DX 1H cumulative revenue growth YoY, 2Q standalone segment income, and the change in segment margin from 1Q.
5. Cash, Borrowings, and Operating Cash Flow
- Previous Quarter: 1Q-end cash and deposits were JPY 1.446B (down JPY 287M from the prior fiscal year-end). Accounts receivable and contract assets were JPY 1.046B (down JPY 459M).
- Previous Quarter: Borrowings comprised JPY 2.6B short-term, JPY 396M current portion of long-term, and JPY 875M long-term, totaling JPY 3.871B (our estimate).
- Previous Quarter: Interest expense rose to JPY 17M (from JPY 10M a year earlier), weighing on non-operating income/expenses.
- Previous Quarter: Investment securities increased to JPY 2.295B (up JPY 202M from the prior fiscal year-end). The equity ratio was 40.3%.
- Previous Quarter: FY3/26 operating CF was JPY 258M, and investing CF was JPY -2.486B.
- To Verify This Quarter: With software investment (software in progress of JPY 415M) and equity-linked drug discovery support continuing, we want to see whether operating CF can fund these investments.
- Key Metrics: 1H cumulative operating CF vs. JPY -102M in the prior-year period, plus 2Q-end cash and deposits and borrowings.
Key Timely Disclosures During the Quarter
- 2026/10/29FRONTEO and Maruho launch second co-creation project on drug target discovery in dermatology - This follow-on project builds on the results of the first phase. It demonstrates repeat business in co-creation projects and could add to AI drug discovery revenue from 3Q onward.
- 2026/10/27FRONTEO and Otsuka Pharmaceutical launch co-creation project on drug target discovery in nephrology - A new co-creation deal with a major pharmaceutical company, showing DDAIF's expanding client base. The P&L impact will come from 3Q onward, so management's comments on the deal pipeline at the 2Q briefing will be key.
- 2026/09/03FRONTEO and Chiome Bioscience begin joint research to create bispecific antibody drugs - The partnership combines DDAIF with antibody drug discovery technology, targeting candidate creation and out-licensing during FY2027. Near-term revenue contribution will be limited, but the deal expands the out-licensing pipeline and supports the medium- to long-term investment case.
Previous Quarter Results (FY3/27 1Q Actual)
The company operates three businesses built around its equation-driven AI, "KIBIT": Life Science AI, Risk Management, and DX. Legal Tech AI and compliance support for financial institutions provide the earnings base. AI drug discovery (DDAIF) offers discontinuous upside, including out-licensing and royalties. Arunettsu, acquired in April 2025, runs the DX business and has grown to about 40% of consolidated revenue (our estimate). The FY3/27 plan is 2H-weighted, with revenue of JPY 7.6B (-0.6%) and operating income of JPY 300M (-59.4%). 1Q ended in an operating loss, which management said was in line with expectations.
| Item | Amount | YoY | vs. Company Plan | Notes |
|---|---|---|---|---|
| Revenue | JPY 1.632B | +5.6% | - | DX and AI drug discovery grew; Risk Management fell 18.6% |
| Operating Income | JPY -179M | - | - | Prior year: JPY -82M. Gross margin fell from 52.4% to 38.7% |
| Recurring Profit | JPY -138M | - | - | Prior year: JPY -95M. Includes dividend income of JPY 46M |
| Net Income | JPY -105M | - | - | Extraordinary gains of JPY 17M, mainly JPY 13M from reversal of foreign currency translation adjustments |
| EPS | JPY -2.69 | - | - | Prior year: JPY -4.10. Full-year EPS guidance: JPY 3.82 |
Guidance Achievement Rate (Recurring Profit Basis): Not calculated. With a 1Q recurring loss of JPY 138M, progress against the full-year target of JPY 250M is not meaningful (prior year: -). For reference, revenue progress against the full-year plan was 21.5% (our estimate), versus 20.2% of full-year actual revenue in the prior-year period (our estimate).
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.